The application of an artificial neural network and pharmacokinetic simulations in the design of controlled-release dosage forms

被引:58
作者
Chen, YX
McCall, TW
Baichwal, AR
Meyer, MC [1 ]
机构
[1] Univ Tennessee, Coll Pharm, Dept Pharmaceut Sci, Memphis, TN 38163 USA
[2] Penwest Pharmaceut Co, Patterson, NY 12563 USA
关键词
artificial neural network; controlled release; dissolution; simulations;
D O I
10.1016/S0168-3659(98)00171-0
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The objective of this work is to use an artificial neural network (ANN) and pharmacokinetic simulations in the design of controlled-release formulations with predictable in vitro and in vivo behavior. Seven formulation variables and three other tablet variables (moisture, particle size and hardness) for 22 tablet formulations of a model sympathomimetic drug were used as the ANN model input, and in vitro dissolution-time profiles at ten different sampling times were used as output. An ANN model was constructed by selecting the optimal number of iterations and model structure (the number of hidden layers and number of hidden layer nodes). The optimized ANN model was used for prediction of formulations based on two desired target in vitro dissolution-time profiles and two desired bioavailability profiles. For three of the four predicted formulations there was very good agreement between the ANN predicted and the observed in vitro and simulated in vive properties. This work illustrates the potential for an artificial neural network, along with pharmacokinetic simulations, to assist in the development of complex dosage forms. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:33 / 41
页数:9
相关论文
共 13 条
[1]   ARTIFICIAL NEURAL NETWORKS - IMPLICATIONS FOR PHARMACEUTICAL SCIENCES [J].
ACHANTA, AS ;
KOWALSKI, JG ;
RHODES, CT .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1995, 21 (01) :119-155
[2]  
*AI WAR INC, 1995, MAN CAD CHEM CUST FO
[3]  
EKUBE NK, 1997, PHARM DEV TECHNOL, V2, P225
[4]   Artificial neural networks as a novel approach to integrated pharmacokinetic-pharmacodynamic analysis [J].
Gobburu, JVS ;
Chen, EP .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1996, 85 (05) :505-510
[5]   QUANTITATIVE STRUCTURE-PHARMACOKINETIC RELATIONSHIPS (QSPR) OF BETA-BLOCKERS DERIVED USING NEURAL NETWORKS [J].
GOBBURU, JVS ;
SHELVER, WH .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (07) :862-865
[6]   APPLICATION OF NEURAL COMPUTING IN PHARMACEUTICAL PRODUCT DEVELOPMENT [J].
HUSSAIN, AS ;
YU, XQ ;
JOHNSON, RD .
PHARMACEUTICAL RESEARCH, 1991, 8 (10) :1248-1252
[7]  
HUSSAIN AS, 1997, IN VITRO IN VIVO COR, P149
[8]  
McCulloch Warren S., 1943, BULL MATH BIOPHYS, V5, P115, DOI 10.1007/BF02459570
[9]   THE ADVANTAGES BY THE USE OF NEURAL NETWORKS IN MODELING THE FLUIDIZED-BED GRANULATION PROCESS [J].
MURTONIEMI, E ;
YLIRUUSI, J ;
KINNUNEN, P ;
MERKKU, P ;
LEIVISKA, K .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1994, 108 (02) :155-164
[10]  
Shah VP, 1997, SCI FDN REGULATING D, P205